Eli Lilly is the dominant player in incretin obesity and diabetes care. Tirzepatide — Mounjaro for type-2 diabetes, Zepbound for obesity — generated the bulk of 2025 growth, and SURMOUNT-5, the first definitive Phase 3B head-to-head against semaglutide, read out 21.6% mean weight loss at 72 weeks versus semaglutide's 15.4%. Q1 2026 revenue reached $19.8 billion (+56% YoY) on Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%); Lilly raised 2026 guidance to $82–85B on April 30 and the stock climbed 6.11% on May 1. On May 4, an FAERS hepatic-failure case for Foundayo surfaced, sending shares down 3% premarket before recovering on Lilly's safety-data response and an RBC 'baseline noise' defense.
The next layer determines 2027 and beyond. Orforglipron, marketed as Foundayo, became the first small-molecule oral GLP-1 cleared for obesity in April 2026 and reached roughly 20,000 patients and more than 8,000 prescribers in its first three weeks, though Wegovy pill outpaced it ~20× in early-May IQVIA volume. Retatrutide, the GLP-1/GIP/glucagon triple agonist, posted its first Phase 3 type-2 diabetes readout (TRANSCEND T2D1: A1c down 1.7–2.0 pts, 25–37 lb mean weight loss) on the April 30 call alongside the prior TRIUMPH-4 obesity-with-knee-osteoarthritis data. The retatrutide MASLD Phase 3 (NCT06859268) is enrolling, building on 86% Phase 2 liver-fat reduction. LillyDirect handles self-pay distribution.
The company has spent 2024 and 2025 building peptide CDMO capacity to support both branded volume and the long shadow of the compounding fight. Stories here track the pipeline, deals, and the share-price moves that follow them.
Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.
Eli Lilly shares closed down nearly 2% at $918.56 and Novo Nordisk fell ~4% on April 22 after CVS Health's decision to opt out of the Medicare obesity drug coverage pilot triggered CMS to scrap the BALANCE model. The combined market cap loss across the two GLP-1 leaders exceeded $25 billion. Hims & Hers dropped another 6% on continued Amazon One Medical competitive pressure.
Eli Lilly announced positive topline results from ACHIEVE-4, the longest Phase 3 study of Foundayo (orforglipron) to date in 2,700+ adults with type 2 diabetes across 15 countries. The pre-planned analysis showed a 57% lower risk of all-cause death (HR 0.43, p=0.002), while meeting non-inferiority for the prespecified cardiovascular endpoint (HR 0.84). Lilly plans to submit Foundayo for type 2 diabetes to the FDA by end of Q2.
BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.
Motley Fool analysis argues that retatrutide — Lilly's triple GLP-1/GIP/glucagon agonist showing up to 28.7% weight loss in Phase 3 TRIUMPH-4 — is the one thing that could firmly cement Lilly's dominance in the obesity drug market. With seven additional Phase 3 readouts expected in 2026 and a projected 2028 launch, retatrutide positions Lilly to extend its lead over Novo Nordisk.
The FDA asked Eli Lilly for additional safety data on liver injury linked to Foundayo (orforglipron), plus post-marketing trials to assess cardiovascular event risk and delayed gastric emptying. A lactation study was also required. The letter, signed April 1, was published April 14 — just two weeks after the drug's fast-track approval under the National Priority Voucher program.
UBS analysts forecast 5-6 million Foundayo prescriptions in 2026, projecting roughly $2 billion in launch-year sales. RBC Capital Markets projects peak annual US sales of $36 billion. Eli Lilly pre-stocked $1.5 billion of inventory ahead of the April 6 retail launch.
CNBC reports Eli Lilly's Indian GLP-1 market share fell from 61% to 56% in March as 26 generic semaglutide brands from 13 companies entered the market following patent expiry. Novo Nordisk held steady at 25% after slashing Ozempic prices 38% and Wegovy prices 48%, while Lilly's Mounjaro remains priced 10x above the cheapest generics.
Eli Lilly's triple-agonist retatrutide met all primary and key secondary endpoints in Phase III TRIUMPH-4. The 9mg and 12mg doses achieved significant weight loss and knee pain reduction at 68 weeks in patients with obesity and osteoarthritis. Seven more Phase III readouts expected in 2026.
Phase 3 SURMOUNT-4 data show patients who continued tirzepatide achieved further weight loss, while those switched to placebo regained ~14% body weight over 52 weeks. Findings underscore the need for long-term GLP-1/GIP therapy continuation.
Detailed comparison of Lilly's Foundayo (orforglipron) and Novo's oral Wegovy. Foundayo offers no food/water restrictions; oral Wegovy has brand familiarity and head start. Wall Street predicts slower initial Foundayo uptake.
Eli Lilly formally launched Foundayo (orforglipron) eight days after FDA approval, having pre-stocked $1.5 billion worth of the drug. The oral obesity market now features a direct Lilly vs Novo Nordisk competition.
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.
Biopharma acquisitions surged in Q1 2026 with 14 deals over $500M. Eli Lilly earned $65.2 billion in 2025, roughly half from Mounjaro and Zepbound, fueling an industry-wide M&A wave.
Eli Lilly launched Foundayo on April 1 at $25/month for insured patients and $149 self-pay. The ATTAIN-1 trial showed 12.4% average body weight loss on the highest dose.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.